NATCO Pharma Limited (BOM:524816)
845.15
+5.75 (0.69%)
At close: Apr 23, 2025
NATCO Pharma Revenue
NATCO Pharma had revenue of 4.75B INR in the quarter ending December 31, 2024, a decrease of -37.41%. This brings the company's revenue in the last twelve months to 42.80B, up 11.76% year-over-year. In the fiscal year ending March 31, 2024, NATCO Pharma had annual revenue of 40.02B with 47.76% growth.
Revenue (ttm)
42.80B
Revenue Growth
+11.76%
P/S Ratio
3.53
Revenue / Employee
10.66M
Employees
4,016
Market Cap
151.26B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
Mar 31, 2021 | 20.56B | 1.41B | 7.37% |
Mar 31, 2020 | 19.15B | -1.80B | -8.57% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,409.52B |
Infosys | 1,647.16B |
Bajaj Finance | 358.05B |
NATCO Pharma News
- 16 days ago - NATCO Pharma plans to launch generic Risdiplam in India, awaiting court clearance - Business Upturn
- 20 days ago - Natco Pharma shares fall 5% today as Trump warns of aggressive pharma tariffs - Business Upturn
- 21 days ago - Natco Pharma shares rally over 5% as U.S. exempts Indian generics from tariff blow - Business Upturn
- 2 months ago - Stocks hitting 52-week low today, February 20: Natco Pharma, VIP Industries, Birlasoft and more - Business Upturn
- 2 months ago - Stocks hitting 52-week low today, February 19: Natco Pharma, Godrej Consumer, Trident, BEML and more - Business Upturn
- 2 months ago - Natco Pharma Ltd (BOM:524816) Q3 2025 Earnings Call Highlights: Navigating Challenges with ... - GuruFocus
- 2 months ago - Natco Pharma shares drop 30% in 2 days following poor Q3 results - Business Upturn
- 2 months ago - Top market losers: Natco Pharma plunges 18.65%, Vijaya Diagnostic down 7.20%, Godfrey Phillips slips 4.18% - Business Upturn